{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:04:57Z","timestamp":1771851897946,"version":"3.50.1"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,4,19]]},"DOI":"10.1001\/jama.2022.3848","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T15:32:59Z","timestamp":1648481579000},"page":"1447","source":"Crossref","is-referenced-by-count":4,"title":["Enhancing HIV Prevention With New Modalities and Routine Sexual History Discussions"],"prefix":"10.1001","volume":"327","author":[{"given":"Kenneth H.","family":"Mayer","sequence":"first","affiliation":[{"name":"Harvard Medical School, Harvard University, and The Fenway Institute, Fenway Health, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lao-Tzu","family":"Allan-Blitz","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Brigham and Women\u2019s Hospital, Division of Global Health Equity, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"jvp220026r2","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s12325-020-01295-0","article-title":"Barriers to the wider use of pre-exposure prophylaxis in the United States.","volume":"37","author":"Mayer","year":"2020","journal-title":"Adv Ther"},{"key":"jvp220026r5","doi-asserted-by":"crossref","DOI":"10.7326\/M21-1548","article-title":"Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis.","author":"Neilan","year":"2022","journal-title":"Ann Intern Med"},{"issue":"23","key":"jvp220026r6","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection.","volume":"373","author":"Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"jvp220026r7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women.","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"jvp220026r8","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.2019.6390","article-title":"Preexposure prophylaxis for the prevention of HIV infection.","volume":"321","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"jvp220026r9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jama.2022.0420","article-title":"Long-acting cabotegravir for HIV prevention: issues of access, cost, and equity.","volume":"327","author":"Sharfstein","year":"2022","journal-title":"JAMA"},{"issue":"14","key":"jvp220026r10","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/jama.2019.2947","article-title":"Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection.","volume":"321","author":"Traeger","year":"2019","journal-title":"JAMA"},{"key":"jvp220026r1","unstructured":"CDC. HIV prevention pill not reaching most Americans who could benefit\u2014especially people of color. News release. March 6, 2018. Accessed August 7, 2019. https:\/\/www.cdc.gov\/nchhstp\/newsroom\/2018\/croi-2018-PrEP-press-release.html"},{"key":"jvp220026r3","unstructured":"CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: a clinical practice guideline. Accessed December 19, 2021. https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2021.pdf"},{"key":"jvp220026r4","unstructured":"CDC. National strategic plan: a roadmap to end the epidemic for the United States\u20142021-2025. Accessed December 19, 2021. https:\/\/files.hiv.gov\/s3fs-public\/HIV-National-Strategic-Plan-2021-2025.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2790710\/jama_mayer_2022_vp_220026_1649698915.03457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T15:39:14Z","timestamp":1650382754000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2790710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":10,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.3848","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}